The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation

Biochemical Journal

Volumn 351, Issue 1, 2000, Pages 273-279

  Sebastiao, M P ^a   Merlini, G ^a   Saraiva, M J ^a   Damas, A M ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Amyloid inhibitor; Crystallography; Molecular modelling; Transthyretin anthracycline complex

Indexed keywords

4' IODOESORUBICIN; AMYLOID; AMYLOID PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; OLIGOMER; PREALBUMIN;

AMYLOIDOSIS; ARTICLE; CRYSTALLIZATION; DISSOCIATION; DRUG PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE;

AMINO ACID SUBSTITUTION; AMYLOIDOSIS; CRYSTALLIZATION; DOXORUBICIN; HUMAN; IODINE; LEUCINE; MODELS, MOLECULAR; PREALBUMIN; PROLINE; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SUPPORT, NON-U.S. GOV'T; THIAZOLES; X-RAY DIFFRACTION;

EID: 0034306113     PISSN: 02646021     EISSN: None     Source Type: Journal    
DOI: 10.1042/0264-6021:3510273     Document Type: Article

References (32)

1. Transthyretin (prealbumin) in familial amyloidotic polyneuropathy: Genetic and functional aspects
2. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein
3. Structure of prealbumin: Secondary, tertiary and quaterna y interactions determined by Fourier refinement at 1.8 Å
4. Transthyretin mutations in health and disease
5. Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement
6. Crystallisation and preliminary X-ray diffraction studies of Leu-55Pro variant transthyretin
7. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution
8. 4'-lodo-4'-deoxydoxorubicin (I-DOX) disrupts the fibrillar structure of transthyretin amyloid
9. New drug therapy of amyloidosis: Resorption of AL-type deposits with 4'-iodo-4'-deoxydoxorubicin
10. Treatment of AL amyloidosis with 4'-iodo-4'-deoxydoxorubicin: An update
11. Thyroxine binding to transthyretin Met 119
12. In vitro amyloid formation from transthyretin: The influence of ions and the amyloidogenicity of TTR variants
13. The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-Met variant to 1.7 Å resolution
14. Molecular surface recognition: Determination of geometric fit between proteins and their ligands by correlation techniques
15. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG)
16. Molecular docking using surface complementarity
17. The crystal structure of amyloidogenic Leu55 Pro transthyretin variant reveals a possible pathway for transthyretin polymerisation into amyloid fibrils
18. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity
19. A systematic study of low-resolution recognition in protein-protein complexes
20. Binding of Mercuri-iodide and related ions to crystals of sperm whale metmyoglobin
21. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions
22. Chemical and biological characterisation of 4'-iodo-4'-deoxydoxorubicin
23. Evaluation of 4'-iodo-4'-deoxydoxorubicin induced cardiotoxicity in two experimental rat models
24. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iododoxorubicin
25. Cardiac toxicity and anti-tumour activity of 4'-deoxy-4'-iododoxorubicinol
26. Toxicity, pharmacokinetics and metabolism of iododoxorubicin in cancer patients
27. Early cardiac toxicity of 4'-iodo-4'-deoxydoxorubicin
28. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters
29. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer β-amyloid fibril formation